Triple VPI CGS 35601 Reduces High Blood Pressure in Low-Renin,High-Salt Dahl Salt-Sensitive Rats

Abstract

We previously reported that CGS 35601, a potent triple inhibitor of angiotensin-converting enzyme, neutral endopeptidase, and endothelin-converting enzyme 1, completely normalized mean arterial blood pressure (MABP) in 36-week-old spontaneously hypertensive rats, a normal renin model. The aim of the present study was to determine the effects of this triple vasopeptidase inhibitor (VPI) on the hemodynamic profile of instrumented, conscious, and unrestrained Dahl salt-sensitive (DSS) rats, a gene-prone, high-salt diet–induced low-renin hypertension model. Male DSS rats (mean weight [±SEM], 385 ± 10 g) were fed a normal diet (Group 1) or a high-salt diet (Groups 2 and 3; 8% NaCl in food) for 6 weeks and then instrumented with a carotid catheter and placed individually in metabolic cages for 30 days. The hemodynamic, hematological, and biochemical profiles were assessed daily. Dose-dependent treatment started after a 7-day stabilization period in Groups 1 and 2 (vehicle dosage, 250 μl/hr) and Group 3 (CGS 35601 dosages of 0.1, 1, and 5 mg/kg/day for 6 days per dose by means of constant intra-arterial infusion), followed by a 5-day washout period. Two additional groups included normotensive Wistar rats (Group 4) and DSS rats that received a double high-salt solid (8% NaCl) and liquid (1% NaCl) diet (Group 5).The MABP in rats receiving CGS 35601 decreased in a dose-dependent fashion toward the baseline level observed in DSS rats receiving a normal diet. The heart rate was unaffected. The hemodynamic profile returned to normal during the washout period. This novel triple VPI is a potent and effective antihypertensive agent with a safe short-term profile that may be of interest for treating hypertension and other cardiovascular diseases. Other hypertensive rat models are being tested.

Get full access to this article

View all access options for this article.

References

Manning RD Jr., Meng S, Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 179:243–250, 2003.

Manning RD Jr., Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol 25:311–317, 2005.

Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 28:191–202, 2005.

Takeda Y. Role of cardiovascular aldosterone in hypertension. Curr Med Chem Cardiovasc Hematol Agents 3:261–266, 2005.

Yamamoto K, Masuyama T, Sakata Y, Mano T, Nishikawa N, Kondo H, Akehi N, Kuzuya T, Miwa T, Hori M. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 47:274–283, 2000.

Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45:1145–1152, 2005.

Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Hori M. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 20:753–761, 2002.

Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10:83–89, 2004.

Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051–2059, 2001.

10.

Mellin V, Jeng AY, Monteil C, Renet S, Henry JP, Thuillez C, Mulder P. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 46:390–397, 2005.

11.

Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 44:S211–S215, 2004.

12.

Nantel F, Daull P, Duta DN, Blouin A, Berthiaume N, Cayer J, Beaudoin M, Belleville K, Benrezzak O, Sirois P, Battistini B. Integrated in vivo pharmacology using an instrumented, unrestrained and conscious rat platform: application to rat models of diabetes. J Pharmacol Toxicol Methods. 2005 Nov 6 [Epub ahead of print].

13.

Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 18: 1606–1613, 2005.

14.

Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 44:186–190, 2004.

15.

Muller DN, Fiebeler A, Park JK, Dechend R, Luft FC. Angiotensin II and endothelin induce inflammation and thereby promote hypertension-induced end-organ damage. Clin Nephrol 60(Suppl 1):S2–S12, 2003.

16.

Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule? Med Sci Monit 11:RA155–RA162, 2005.

17.

Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 23:401–409, 2005.

18.

Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 68:456–463, 2005.

19.

Elmarakby AA, Morsing P, Pollock JS, Pollock DM. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. Vascul Pharmacol 40:253–259, 2003.

20.

Inguimbert N, Poras H, Teffo F, Beslot F, Selkti M, Tomas A, Scalbert E, Bennejean C, Renard P, Fournie-Zaluski MC, Roques BP. N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg Med Chem Lett 12:2001–2005, 2002.

21.

Daull P, Blouin A, Beaudoin M, Gadbois S, Belleville K, Cayer J, Berthiaume N, Sirois P, Nantel F, Jeng AY, Battistini B. The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601. Exp Biol Med 231:824–829, 2006.